Overview
DGX market data
Price History
DGX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for DGX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260Benzinga · Jul 24, 2026, 6:41 PM
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250Benzinga · Jul 24, 2026, 6:08 PM
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250Benzinga · Jul 24, 2026, 3:08 PM
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255Benzinga · Jul 24, 2026, 11:33 AM
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is WinningBenzinga · Jul 23, 2026, 5:47 PM
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 23, 2026, 2:20 PM
Transcript: Quest Diagnostics Q2 2026 Earnings Conference CallBenzinga · Jul 23, 2026, 1:33 PM
Quest Diagnostics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates.Benzinga · Jul 23, 2026, 12:43 PM
Earnings Scheduled For July 23, 2026Benzinga · Jul 23, 2026, 11:11 AM
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 Est; Raises FY2026 Sales Guidance from $11.780B-$11.900B to $11.950B-$12.050B vs $11.851B EstBenzinga · Jul 23, 2026, 10:47 AM